Market Overview

UPDATE: Swedbank Downgrades AstraZeneca to Reduce on Valuation

Related AZN
Benzinga's Top Upgrades, Downgrades For March 19, 2018
Height Casts 65% Odds That Congress Rolls Back Pharma Discounts
AstraZeneca's Farxiga shows positive effect in late-stage study in type 2 diabetics with moderate renal impairment (Seeking Alpha)

Swedbank lowered its rating on AstraZeneca (NYSE: AZN) from Neutral to Reduce as the company faces price pressures ahead.

Swedbank commented, "Increasing the focus on productivity and innovation is exciting, but after spending USD 23bn over 5 years, execution and transparency is critical. AZN is facing price pressure, soft launch support and a period of underperforming emerging markets. Despite AZN's attractive direct yield, we downgrade to Reduce (Neutral) and await improved transparency."

AstraZeneca closed at $46.70 on Thursday.

Latest Ratings for AZN

Mar 2018JefferiesUpgradesHoldBuy
Feb 2018Leerink SwannMaintainsMarket PerformMarket Perform
Dec 2017JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: SwedbankAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (AZN)

View Comments and Join the Discussion!